Reportlinker.com

Reportlinker.com

September 10, 2008 16:19 ET

Get a Deep Insight into the Global Cancer Treatment Forecast to 2012

LONDON, UNITED KINGDOM--(Marketwire - Sept. 10, 2008) - Reportlinker.com announces that a new market research report related to the Oncology industry is available in its catalogue.

Global Cancer Treatment Forecast to 2012

http://www.reportlinker.com/p091964/Global-Cancer-Treatment-Forecast-to-2012.html

High number of unmet needs and an ever-increasing prevalence of cancer has created a gold rush among drug companies to enter the cancer market. Here, launching a drug successfully is risky, however, if launched, commercial gains completely surpass the expenditures incurred, says ````Global Cancer Treatment Forecast to 2012", the new research report from RNCOS.

Cancer represents the fastest growing therapy segment in the pharmaceutical market. This segment has become the centre of focus for drug firms and investors, and has garnered more attention than any other therapy segment; nearly every mid-size and large pharmaceutical/biotech company today is linked to a cancer pipeline.

Drugs available in the market today do give some respite to patients but fail to address a number of complications. So manufacturers are working to solve the problem and in future, we may see a number of drug launches which will significantly reduce the complications and increase life expectancy significantly.

This report is a comprehensive study on the global cancer market and gives statistics and analysis on cancer prevalence, market size, market structure, key drug segments, market share of key players and drugs, major opportunity areas and trends in technology development. Both the past and current market trends have been covered in the report along the factors that are expected to impact the market in future. This report provides answers to a number of questions vital for firms looking for making an investment into the sector.

Key Findings

- From more than 12 Million newly diagnosed cancer cases in 2007, the number of newly diagnosed global cancer cases is expected to reach over 17 Million by 2020.

- Growing at a CAGR of 12.3% between 2007 and 2012, the global market for cancer drugs is expected to cross US$ 78 Billion by 2012.

- Cancer vaccines and antiangiogenics will record the fastest growth rate between 2007 and 2012.

- Drug manufactures are now focused on developing target therapies. These drugs attack target cells and thus limit the severity of side effects.

- The US is the largest market for cancer drugs, followed by Europe and Japan.

- Drugs for cancer represent the largest therapy area under clinical development; however, when it comes to approval rates, drugs for cancer have the worst approval rates.

Key Issues Analyzed

- Evaluation of past, current and future market trends.

- Discussion on major cancer drugs and their markets.

- Future forecast of the cancer market.

- Analysis of various challenges and opportunities for the industry.

- Categories of players operating in the market and their present and future revenue forecast.

- Analysis of key Geographical markets

Research Methodology Used

Information Sources

The information given in the report has been sourced from various credible sources like books, newspapers, trade journals, white papers, industry portals, government agencies, trade associations, monitoring industry news and developments, and through access to over 3000 paid databases.

Analysis Methods

The analysis methods used in the report include ratio analysis, historical trend analysis, linear regression analysis using software tools, judgmental forecasting, and cause and effect analysis.


1. Analyst View
2. The Global Burden of Cancer
2.1 Cancer - A Leading Cause of Death
2.2 Prevalence
2.3 Factors Inducing Cancer
3. Global Cancer Market
3.1 Market Size
3.2 Market Segmentation
3.3 Drug Pipelines
3.4 Key Players
3.5 Key Drugs
4. Current & Future Treatments
4.1 Chemotherapy


4.1.1 Introduction
4.1.2 Market Analysis


4.1.2.1 Plant Alkaloids
4.1.2.2 Alkylation Agents
4.1.2.3 Anti-metabolites
4.1.2.4 Platinum Compounds
4.1.2.5 Cytotoxic Antibiotics
4.1.2.6 Other Cytostatics

4.2 Antiangiogenics


4.2.1 Introduction
4.2.2 Market Analysis

4.3 Hormone Therapy


4.3.1 Introduction
4.3.2 Market Analysis

4.4 Monoclonal Antibodies


4.4.1 Introduction
4.4.2 Market Analysis

4.5 Vaccines


4.5.1 Introduction
4.5.2 Market Analysis

5. Key Markets
5.1 US


5.1.1 Prevalence
5.1.2 Market Analysis

5.2 Europe


5.2.1 Prevalence
5.2.2 Market Analysis

5.3 Japan


5.3.1 Prevalence
5.3.2 Market Analysis

5.4 India & China


5.4.1 Prevalence
5.4.2 Market Analysis

6. Opportunities
6.1 Drug Delivery & Packaging Market
6.2 Diagnostic Devices
6.3 Cancer Generics
6.4 Contract Research & Manufacturing
7. Roadblocks
7.1 High Clinical Failure Rates
7.2 Reimbursements
7.3 Affordability
7.4 Side Effects
List of Figures:
Figure 2-1: Global - Leading Causes of Death (%), 2005E
Figure 2-2: Global - New Cancer Cases(i) (in Million), 2002, 2007,
 2012F & 2020F
Figure 2-3: Global - New Cancer Cases(i) in Males by Type (%), 2007E
Figure 2-4: Global - New Cancer Cases(i) in Females by Type (%), 2007E
Figure 2-5: Global - New Cancer Cases by Region (in Number), 2007E
Figure 2-6: Global - Leading Causes of Cancer (%)
Figure 3-1: Global - Cancer Market (in Billion US$), 2007-2012F
Figure 3-2: Global - Cancer Market by Drug Type (%), 2007
Figure 3-3: Global - Forecast for Cancer Market by Drug Type (%), 2012
Figure 3-4: Global - Drugs under Clinical Development by Therapy Area (%),
 2007
Figure 3-5: Global - Cancer Drugs by Type in Phase-II Clinical Development
 Process (%), 2006
Figure 3-6: Global - Cancer Drugs by Type in Phase-III Clinical Development
 Process (%), 2006
Figure 3-7: Global - In-licensing Deals by Therapy Area (%), 2006
Figure 4-1: Global - Chemotherapy Market (in Million US$), 2007-2012F
Figure 4-2: Global - Plant Alkaloids Market (in Million US$), 2007-2012F
Figure 4-3: Global - Alkylation Agents Market (in Million US$), 2007-2012F
Figure 4-4: Global - Anti-metabolites Market (in Million US$), 2007-2012F
Figure 4-5: Global - Platinum Compounds Market (in Million US$), 2007-2012F
Figure 4-6: Global - Cytotoxic Antibiotics Market (in Million US$),
 2007-2012F
Figure 4-7: Global - Other Cytostatics Market (in Million US$), 2007-2012F
Figure 4-8: Global - Antiangiogenics Market (in Million US$), 2007-2012F
Figure 4-9: Global - Hormone Therapy Market for Cancer Treatment
 (in Million US$) 2007-2012F
Figure 4-10: Global - Hormone Therapy Market Segmentation for Cancer
 Treatment (%), 2004 & 2014F
Figure 4-11: Global - Monoclonal Antibodies Market (in Million US$),
 2007-2012F
Figure 4-12: Global - Cancer Vaccine Market (in Million US$), 2006,
 2007E & 2012F
Figure 4-13: Global - Cancer Vaccine by Type in various Phases of Clinical
 Development (in Number), Aug 2005
Figure 5-1: US - New Cancer Cases(i) (in Number), 2005, 2008F & 2012F
Figure 5-2: US - Cancer Market (in Million US$) 1999, 2004, 2007E & 2012F
Figure 5-3: US - Cancer Market by Therapy Area (%) 1999, 2004, 2007E & 2012F
Figure 5-4: Europe - New Cancer Cases(i) (in Number), 2004, 2006 & 2012F
Figure 5-5: Europe - Cancer Market (in Billion US$), 2004, 2007E & 2012F
Figure 5-6: Japan - Cancer Market (in Billion US$), 2005, 2007E & 2012F
Figure 5-7: India - New & Total Number of Cancer Patients (in Million)
Figure 5-8: China - New & Total Number of Cancer Patients (in Million)
Figure 5-9: India - Cancer Market (in Million US$), 2007 & 2012F
Figure 6-1: Global - Cancer Drug Delivery Market (in Billion US$), 2005E,
 2010F & 2015F
Figure 6-2: Global - Cancer Diagnostics Market (in Billion US$), 2002,
 2007E & 2012F
Figure 6-3: Global(i) - Cancer Drugs going Off-patent (in Billion US$),
 2008-2014
Figure 6-4: Global(i) - Cancer Generic Market (in Billion US$), 2004, 2005,
 2007E & 2014F
Figure 6-5: Global(i) - Cancer Generic Market by Country (%), 2005
Figure 7-1: Success Rates of Drugs by Therapy Area from First in Man to
 Registration (%)
List of Tables:
Table 2-1: Global - New Cancer Cases(i) in Males by Type (in Number), 2007E
Table 2-2: Global - New Cancer Cases(i) in Females by Type (in Number),
 2007E
Table 3-1: Global - Revenues from Major Therapy Areas (in Million US$),
 2007 & 2012F
Table 3-2: Global - Growth of various Cancer Drugs (%), 2007-2012
Table 3-3: Global - Sales of Top Companies in Cancer Market(i)
 (in Million US$), 2007
Table 3-4: Global - Forecast for Sales of Top Companies in Cancer Market(i)
 (in Million US$), 2012
Table 3-5: Global - Sales(i) of Top Cancer Drugs (in Billion US$), 2002
Table 3-6: Global - Sales(i) of Top Cancer Drugs (in Billion US$), 2006
Table 3-7: Global - Forecast for Sales(i) of Top Cancer Drugs
 (in Billion US$), 2012
Table 5-1: US - New Cancer Cases(i) for Selected Cancer Sites (in Number),
 2008F
Table 5-2: US - Key Players in the Cancer Market by Rank (2000 & 2005)
Table 5-3: Europe - New Cancer Cases in Top 5 Countries (in '000), 2006
Table 5-4: Japan - Leading Sites of Cancer Incidences in Males &
 Females (%), 2001
Table 6-1: Global - Cancer Diagnostics Market by Type of Test
 (in Million US$), 2002-2006E

To order this report:

Global Cancer Treatment Forecast to 2012

http://www.reportlinker.com/p091964/Global-Cancer-Treatment-Forecast-to-2012.html

More market research reports here!

Contact Information